Genen­tech's food al­ler­gy med­ica­tion gets pri­or­i­ty re­view nod from the FDA

Genen­tech and No­var­tis’ Xo­lair scored a pri­or­i­ty re­view from the FDA on Wednes­day for the re­duc­tion of al­ler­gic re­ac­tions in adult and pe­di­atric pa­tients 1 year and old­er, the com­pa­ny said, with the agency ex­pect­ed to make a de­ci­sion in the first quar­ter of 2024.

If it’s ap­proved, it would be the first med­i­cine to re­duce al­ler­gic re­ac­tions to mul­ti­ple foods, ac­cord­ing to the com­pa­ny. The FDA ac­cept­ed Genen­tech’s sBLA based on the first stage of the Phase III OUt­MATCH study. That study in­ves­ti­gat­ed Xo­lair, the brand name for oma­l­izum­ab, in pa­tients al­ler­gic to peanuts, milk, eggs and cashews. Pa­tients got ei­ther place­bo or Xo­lair in­jec­tions ei­ther every two or four weeks for 16 to 20 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER